

From: SANTE PHARMACEUTICALS B5
Sent: mardi 21 novembre 2017 12:52
To: [REDACTED]
Cc: [REDACTED] SANTE PHARMACEUTICALS B5
Subject: RE: Bayer request for a meeting on IP Incentives analysis

Dear [REDACTED],

On behalf of [REDACTED], we would like to thank you for your email and interest in the study on the impact of Supplementary Protection Certificates and pharmaceutical incentives on innovation, availability and accessibility of medicinal products.

As you may be aware, the study is currently conducted by the contractor Copenhagen Economics, which has developed a methodology on the basis of the Terms of Reference published in December last year. It is foreseen that stakeholders are consulted in a balanced way to provide data and share experience to the contractor. I understand that EFPIA, of which Bayer is a corporate member, was one of the EU-based organisation consulted and interviewed recently.

Considering the need to ensure a balanced representation of all stakeholders and the fact that the voice of EFPIA's members has already been shared with the consultant, I consider that it would not be appropriate to organise a meeting as an appropriate consultation has already taken place.

Thank you in advance for your understanding,

Best regards,

Unit "Medicines: policy, authorisation and monitoring"



European Commission
DG Health and Food Safety

This message represents solely the views of its author and can not be regarded as the official position of the Commission. It is intended solely for the person to whom it is addressed and may contain confidential information. If you have received this message in error, please notify me as soon as possible.

From: [REDACTED]
Sent: Wednesday, November 15, 2017 2:44 PM
To: [REDACTED]
Subject: Bayer request for a meeting on IP Incentives analysis

Dear [REDACTED],

I am contacting you on behalf of Bayer – a global enterprise with core competencies in the Life Science fields of health care and agriculture, to ask for a meeting to discuss the analysis of the pharmaceutical incentives

currently being conducted by DG Growth and more specifically the Supplementary Patent Certificate (SPC) review.

Pharmaceutical incentives and rewards for innovation are the foundations on which innovation is built. They provide pharmaceutical companies the protection needed to invest in the long, complex and costly process of researching, developing and delivering new medicines to patients and pave the way for future low-cost generics. With over 7000 medicines currently in development, the system is working and able to support a pipeline of this scale with a high risk of failure. These upcoming new treatments will continue to change patients' lives but they would simply not exist without pharmaceutical incentives and rewards for innovation.

We would then appreciate the opportunity to have an exchange of views with you on the topic and introduce in more detail why incentives and rewards are important for our industry and Europe in order to encourage further research and innovation.

I realise of course that your agenda is very busy but would like to propose already a couple of days for the meeting to take place when Bayer's Head of IP Advocacy, [REDACTED], will be in Brussels: Wednesday, 22 November, and Tuesday, 28 November.

I look forward to hearing from you.

As always, should you have any questions please don't hesitate to contact me.

Best wishes,

[REDACTED]

[REDACTED]
EU Health Policy Manager

Bayer: Science For A Better Life

Bayer SA-NV

[REDACTED]

Web: <http://www.bayer.com>

Vorstand: Werner Baumann, Vorsitzender | Liam Condon, Johannes Dietsch, Hartmut Klusik, Kemal Malik, Erica Mann, Dieter Weinand
Vorsitzender des Aufsichtsrats: Werner Wenning
Sitz der Gesellschaft: Leverkusen | Amtsgericht Köln, HRB 48248

The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.
